The Latest in FDA Evaluations and Research

FDA News

Top Stories

As the sun rises in the East and bears visit the woods, we can state with absolute certainty that we will be blitzed with a plethora of “best of”, ”worst of” and “pick of” lists, and of course ‘what’s hot what’s not for 2010” predictions, in the next couple of weeks. And this year it will be worse. Not only do we say goodbye to 2009 but we also move up into a new decade. Copy writers have even greater license to fill a few column inches with those trivial facts that we feign a healthy disinterest in but secretly devour, storing the data to impress our friends and colleagues at some later date. And when the opportunity does arrive to finally impart our new found knowledge, Oh Boy! do we like revelling in our own self importance. We have the sudden urge to give it the old Billy Big Bananas treatment. We’re not content with simply stating that Will Young’s ‘Evergreen’... (more)

UEC: Bundling Windows Image

Creating new disk image This will be the main HDD in the virtual image, so make sure to give it as much space as you’ll need. Since we’re building a kvm image, we can use a qcow2 format for disk images. Qcow2 is an expandable image format, so it’ll only take as much storage space as it’s actually used within the image. $ kvm-img create -f qcow2 win-2k3.img 20G OS Installation Get the iso file of the Windows distribution to be installed in the image. And start the installation process. $sudo kvm -m 1024 -cdrom Win2003_cd1.iso -drive file=win-2k3.img,if=scsi,boot=on -nographic -vnc :0 After finishing the installation and in case the installation needs 2nd CD as well, reboot the VM and launch the VM by the following command. $ sudo kvm -m 1024 -boot c -cdrom Win2003_cd2.iso -drive file=win-2k3.img,if=scsi,boot=on -nographic -vnc :0 Once installation is complete, create the ... (more)

US Government: Playing Jeopardy! with the Cloud

One of the most popular features of our Licensed ZapThink Architect (LZA) SOA course is the Jeopardy! game at the end. With clues taken from the material, the responses as per the television show must be in the form of a question. But while answer-first, question-last pattern may be amusing for a game show, it’s a serious pitfall in the world of IT. In fact, understanding what the proper question should be is an important lesson in the LZA course, as it’s a critical skill for any architect. All too often, however, organizations start with an answer while being unclear on what the question is. Case in point: the US government’s Cloud First initiative. Originally part of former Federal CIO Vivek Kundra’s 25-Point Plan to Reform Federal IT Management, Cloud First called for government agencies to move three existing applications to the Cloud and consider Cloud for an... (more)

Mobile Health News Weekly – Week of October 13, 2013

The Mobile Health News Weekly is an online newsletter made up of the most interesting news and articles related to mobile health that I run across each week.  I am specifically targeting information that reflects market data and trends. Also read Enterprise Mobility Asia News Weekly Also read Field Mobility News Weekly Also read Mobile Commerce News Weekly Also read Mobility News Weekly Rep. Marsha Blackburn has announced she will introduce a bill on mobile health application regulations within the next two weeks. Speaking at a Telecommunications Industry Association event, Blackburn said the bill would "provide the [FDA] with the tools it needs to effectively protect consumers from the high-risk technologies" without enforcing unnecessary oversight on lower-risk technologies.  Read Original Content Stupid Cancer, the dominant youth cancer non-profit in the United States,... (more)

FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis

INDIANAPOLIS, July 23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO((R)) [teriparatide (rDNA origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture. Glucocorticoid therapy is the most common cause of secondary osteoporosis, leading to bone loss and an increased risk for fracture.(1) "Patients who take long-term glucocorticoid therapy are already dealing with a serious health condition, and, on top of that, they may be at a significantly higher risk for fracture," said Vladimir Kopernicky, medical director for Eli Lilly and Company. "The FDA's decision provides these patients with a valuable treatment option for osteoporosis, which they may de... (more)

Quest Diagnostics Empowers the Nation's Physicians to Immediately Embrace ePrescribing

MADISON, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX) today announced plans to make it easy for every physician in the United States to quickly embrace digital healthcare technology with a six-month, risk-free trial of its Care360(TM) ePrescribing service. For physicians currently using its Care360 Labs & Meds service, the company will activate the Care360 ePrescribing service for six months, risk free, enabling them to easily opt in and begin ePrescribing. The company is extending the same opportunity to any physician in the United States interested in trying ePrescribing in their practice without obligation. The offer is available to physicians who begin use of the Care360 ePrescribing service before December 18, 2009. Today, approximately 150,000, or more than 20 percent, of U.S. physicians are connected to Quest Diagnostics Care360 s... (more)

Video: Spherix Announces Positive Interim Results in Phase 3 Trial of Novel, Oral Compound for Type 2 Diabetes

BETHESDA, Md., Nov. 16 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced positive interim Phase 3 clinical results for the planned review of the NEET (Naturlose (D-tagatose) Efficacy Evaluation Trial) trial of D-tagatose in drug naive patients. To view the Multimedia News Release, go to: Results of the blinded interim data analysis of the Phase 3 trial demonstrate a significant reduction in variability of HbA1c levels, the primary endpoint of the trial. The observed data to-date indicate that the change in variability of HbA1c from baseline is favorable, and that the current sample size gives the study suff... (more)

Notal Vision's ForeseeHome(TM) AMD Monitor Receives FDA Clearance

ST. LOUIS, Jan. 27 /PRNewswire/ -- Notal Vision's ForeseeHome(TM) AMD Monitor has received Section 510 (k) clearance from the U.S. Food and Drug Administration (FDA). The ForeseeHome AMD Monitor is the first ophthalmic device linking patients and doctors between eye exams for ongoing monitoring of age-related macular degeneration (AMD). Patients complete a frequent but brief exam on their ForeseeHome AMD Monitor, in the comfort of their own home, and data is transmitted to the patients' eye care physician and the Notal Vision Data Monitoring Center. The award winning ergonomic design of the ForeseeHome AMD Monitor is comfortable and easy to use for patients at risk of vision loss from wet AMD. Wet AMD is the leading cause of blindness in people over the age of 60 in the western world. Recent breakthroughs in treatments place even greater importance on early d... (more)

Merck Serono Announces Outcome of Its Request for Reexamination of CHMP Opinion for Cladribine Tablets in MS

GENEVA, January 21, 2011 /PRNewswire/ -- - CHMP Confirms its Initial Negative Opinion Regarding the Marketing Authorization Application for Cladribine Tablets - Merck Serono Remains Fully Committed to the Potential of Cladribine Tablets to Meet an Unmet Medical Need as an Oral, Short-Course, Disease-Modifying Drug for Multiple Sclerosis Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that following its request for reexamination, the Committee for Medicinal Products for Human Use (CHMP) confirmed its previous position and adopted a final negative opinion regarding the marketing authorization application (MAA) for Cladribine Tablets as a treatment for relapsing-remitting multiple sclerosis (MS). The majority of CHMP members were of the opinion that the benefits of Cladribine Tablets do not outweigh its risks based on data submitted. Howeve... (more)

Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012

ANAHEIM, Calif., Feb. 10, 2012  /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Leerink Swann Global Healthcare Conference to be held on February 15-16, 2012 in New York.  Steve Cartt, Executive Vice President and Chief Business Officer, is scheduled to present an overview of the Company on Thursday, February 16, 2012 at 2:30 p.m. ET.  A live webcast and subsequent archived replay of the presentation will be accessible at  The replay will be available for 90 days after the event. About Questcor                                                                                      Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary ... (more)

American Academy of Dermatology Association Disappointed in Delayed Vote on Idaho Indoor Tanning Legislation

Absurd questions about revenue postpone important health legislation SCHAUMBURG, Ill., March 3, 2012 /PRNewswire-USNewswire/ -- The Idaho Dermatology Society (IDS) and the American Academy of Dermatology Association (AADA) are disappointed in the postponement of the vote by the Idaho House of Representatives on House Bill 486, which would ban the use of indoor tanning beds by minors under the age of 18. The vote was postponed due to the objections of the Idaho Freedom Foundation which raised concerns that passage of the bill would financially benefit dermatologists who would prescribe tanning sessions for certain skin conditions, rather than allowing teens to tan on their own. "The issues raised about this legislation are absolutely ridiculous and dermatologists are disappointed that the Idaho House of Representatives would give more credit to these ludicrous conc... (more)